Stock Investor Insights: Five Innovative Stocks to Buy for Growth Industry Breakthroughs

You are receiving this email because you signed up to receive our free e-letters, or you purchased a product or service from its publisher, Eagle Financial Publications. Five Innovative Stocks to Buy for Growth Industry Breakthroughs 08/03/2021 [Sponsored Content [The Options Trading “Training Video” Retirees Can’t Get Enough Of](]( Options expert Jeff Clark is on a mission to show every American at or near retirement how easy it is to trade options. His 3-Stock Retirement Blueprint show you how to trade better than ever before. [Click here to learn the names and tickers of these 3 stocks.]( [Click Here...]( Five innovative stocks to buy give investors an opportunity to profit from advances occurring in growth industries. Among the five innovative stocks to buy are the world’s largest lithium miner, the developer of a pharmaceutical to treat people suffering from post-traumatic stress disorder (PTSD), a cryptocurrency brokerage firm and two cancer treatment providers. The five innovative stocks to buy are the combined recommendations of two former Wall Street professionals who shared their picks during the recent Global Financial Summit held as part of the [FreedomFest]( conference in Rapid City, South Dakota, drawing a record 2,700-plus attendees. Investors should keep in mind that all five of the innovative stocks are for growth-oriented companies whose shares can be volatile. They are best suited for investors who can afford to weather the ups and downs that come with such holdings. Five Innovative Stocks to Buy Include Lithium Battery Maker Albemarle Albemarle (NYSE:ALB) is the world’s largest miner of lithium, which serves as the main ingredient in batteries used by [electric vehicles]( (EVs). As I have written in previous columns, [electric vehicle manufacturers]( such as Palo Alto, California-based Tesla (NASDAQ:TSLA), Detroit-based [General Motors]( (NYSE:GM), Dearborn, Michigan-based Ford (NYSE:F) and Volkswagen AG (FRA:VOW), of Wolfsburg, Germany, appear destined to remain major competitors in the future of ground transportation. Those electric vehicle manufacturers and others worldwide, including [Nissan]( (OTC:NSANY), [Mitsubishi]( (OTC:MMTOF) and [Toyota]( (NYSE:TM) in Japan, as well as Li Auto (NYSE:LI) in China, have combined to announce spending programs that collectively top $200 billion to design and build the cars and trucks of tomorrow. The funding should well exceed that amount in the coming years. Chart courtesy of [www.StockCharts.com]( Jim Woods, editor of the [Successful Investing]( and [Intelligence Report]( investment newsletters, as well as leader of the [Bullseye Stock Trader]( advisory service and co-head of the [Fast Money Alert]( service with Mark Skousen, PhD, has recommended Tesla profitably in the past. Despite occasional pullbacks, electric vehicle stocks have been trending upward as sales and production of such products have jumped in recent years. Investment Columnist Paul Dykewicz interviews Wall Street veteran Jim Woods. [[A New Way To Cash in on the Crypto Boom](]( You don’t have to invest directly in cryptocurrencies to profit from the crypto revolution. In fact, you can do it using one little-known stock. Over 12 months, shares of this stock skyrocketed from just $6.06 to $73.03 -- a gain of 1,105% in just a year. In other words, had you invested $5,000 in this company a year ago, you could've had an extra $55,250 in your bank account today. [Click here to find out more on this stock.]( [Click Here...]( Cybin Ranks Among Five Innovative Stocks to Buy Cybin Inc. (OTCMKTS:CLXPF) is a medical psilocybin molecule maker that is developing a pharmaceutical for veterans who suffer from post-traumatic stress disorder (PTSD), as well as for those who struggle with anxiety, depression and addiction. It began trading publicly in November 2020 and has been on the rise, as shown by its latest stock chart. Chart courtesy of [www.StockCharts.com]( The potential market for [Cybin]( pharmaceuticals is huge, with an estimated 700 million people worldwide affected by some sort of mental illness, eating disorder or addiction. The company announced it has received approval for the listing of its common shares on the NYSE American LLC stock exchange and that the common shares are expected to begin trading on that exchange on or about August 5, 2021, under the symbol “CYBN.” Woods indicated [Cybin’s listing]( on the NYSE offers a chance to build a bigger investor following for the stock. “As the first psychedelic biotech company that will now trade on this esteemed exchange in the U.S., we will commit resources to reach the broadest investor audience with our mission and will continue to accelerate our efforts to position Cybin as a leader in the sector,” said Doug Drysdale, Cybin’s CEO, in a statement. Five Innovative Stocks to Buy Take the Journey with Voyager Digital Voyager Digital (OTCMKTS:VYGVF) is a cryptocurrency brokerage firm that allows customers to buy and sell Bitcoin, Ethereum, Dogecoin, etc. I personally bought shares in the stock earlier this year in hopes of profiting from increased investor interest in cybersecurity without needing to choose the ultimate winners in a crowded field of cryptocurrency entrants. However, the stock generally trades in the same direction as Bitcoin, so Voyager Digital has trailed off lately along with the cybersecurity, said Woods, who still recommends it. Voyager Digital still could turn into a big victor, despite its volatility. For the past three years, VYGVF is up 13,480%, Woods said. Chart courtesy of [www.StockCharts.com]( Pension Fund Head Favors Fund of Many More Than Five Innovative Stocks to Buy For an investor who wants to benefit from growth companies that will benefit from innovations, but incur less volatility, consider a fund such as Touchstone Sands Capital Select Growth (PTSGX) that offers a diversified portfolio, said Bob Carlson, who also serves as chairman of the Board of Trustees of Virginia’s Fairfax County Employees’ Retirement System with more than $4 billion in assets. The fund has several share classes, but this is the best one for most individual investors, said Carlson, who also heads the [Retirement Watch]( investment newsletter. Chart courtesy of [www.StockCharts.com]( The fund is managed by Sands Capital, which has been an excellent manager for pension funds and other institutional investors for decades, Carlson continued. Most investors don't know about it because the company focuses on institutional clients, he added. “The fund focuses on a small number of growth companies that the fund managers have studied closely and in which they have great confidence,” Carlson said. “Recently, the fund held only 30 stocks and had 58% of the fund invested in the 10 largest positions.” Recent top holdings feature Singapore-based consumer internet company Sea Ltd. (NYSE:SE), Los Gatos, California-based subscription video streaming service Netflix (NASDAQ: NFLX), San Francisco-based digital payments company Square Inc. (NYSE:SQ), San Francisco-based credit card company Visa Inc. (NYSE:V) and Santa Clara, California-based cloud computing provider ServiceNow (NYSE:NOW). The fund has soared 39.02% in the past 12 months and 9.88% so far in 2021, Carlson said. It also has an annualized return of 29.07% over three years, 27.06% over five years, and 18.61% over 10 years. As with most growth funds, it does extremely well when stocks are rising but lags when stocks are flat or falling, Carlson counseled. [[How To Use Technical Indicators (The Right Way)](]( Predictive analysis is revolutionizing the trading space as we know it. With high-accuracy forecasting, traders can dodge losses and squeeze the most out of gains. Our experts want to empower you with the knowledge and education to trade intelligently. Check out today's deep dive into cutting-edge, predictive technical indicators to see the tricks and tips you may not know about. [Click here to register for free.]( [Click Here...]( Cancer Treatment Companies Round out Five Innovative Stocks to Buy Alex Green, a New York Times bestselling author and a former Wall Street veteran who has more than 20 years of experience as a research analyst and an investment advisor, spoke at FreedomFest about two stocks that are pursuing cancer treatments. As a former health communications intern at the National Cancer Institute when I was in graduate school, I am especially interested in such stocks not just as investments but am even more intrigued by their potential to offer vital treatments for those who critically need them. Cancer is second only to heart disease as the biggest cause of death in the United States. The sad reality is that cancer averages more than 18 million new cases worldwide each year, as well as 1.8 million in the United States alone. New Cancer Cases Projected to Surge 63.9% Between Now and 2040 The National Cancer Institute estimates that the number of new cases per year will rise to 29.5 million by 2040. With annual spending on cancer exceeding $150 billion in the United States, investors should keep in mind that cases seem destined to rise amid an aging population in America. Annual expenditures for cancer in the United States currently top $150 billion. One of the most heart-wrenching aspects of cancer is that by the time many patients feel symptoms that seem significant enough to see a doctor, the disease can be in a late stage and metastatic, Green commented. Green expressed hope for a simple blood test that could diagnose cancer early before it has a chance to spread. Such as diagnostic advance would avoid much suffering by patients, as well as create a financial windfall for those who develop and provide it, he added. Exact Sciences Earns Berth Among Five Innovative Stocks to Buy Exact Sciences (Nasdaq: EXAS) is seeking to provide such a diagnostic breakthrough and the Madison, Wisconsin-based company earned Green’s recommendation. He is bullish on the company’s prospects for providing cancer screening and diagnostic tests in the United States and elsewhere in the world. Chart courtesy of [www.StockCharts.com]( The company’s breakout product thus far is Cologuard, a noninvasive DNA screening test to detect colorectal cancer and pre-cancer. Exact Sciences also offers Oncotype DX, a gene expression test for breast, prostate and colon cancers. Its management is seeking for the company’s DNA screening technology to detect all types of cancer and do so earlier than in the past. Its CEO Kevin Conroy recently said the diagnostic advance is "very close." If it happens, Green said it could have a greater effect on human health than any diagnostic ever devised. Novocure Nets Final Spot Among Five Innovative Stocks to Buy Israel-based Novocure (Nasdaq: NVCR) has a novel therapy for treating solid tumor cancers and jumped more than 162 points, or 274%, from the end of June 2020 to June 2021. It remains a recommendation of Green even though the stock stumbled recently after its Phase 2 trial results to treat advanced liver cancer patients. Green described the steep slide as an “overreaction” and called it a new buying opportunity. The stock reached $225.58 just six weeks ago on June 23 before closing at $149.33 for a 33.9% drop. Chart courtesy of [www.StockCharts.com]( The company is an “international oncology leader,” Green said. He cited its operations in the United States, Europe and Asia that produce more than $500 million in annual sales. A notable achievement for Novocure came in 2011 when it launched Optune, its TTFields delivery system, for glioblastoma, a common primary brain cancer and one of the most difficult types to treat. With Food and Drug Administration (FDA) approval obtained in 2015, Optune uses low-intensity electric fields to treat both glioblastoma and mesothelioma, a tumor of the tissue that lines the heart, lungs, stomach and other organs. Studies are ongoing to use the treatment for other brain cancers, as well as for pancreatic, ovarian, liver and lung cancers. Results are due in the next several months. Unlike pharmaceutical products may work only in certain subsets of patients, Novocure's technology is showing effectiveness across the board, Green said. Plus, there are no toxic side effects, he added. New Delta Variant of COVID-19 Causes Increased Cases and Concerns The increasingly transmissible [Delta variant]( of COVID-19 is causing a new surge in cases and raising serious concern from health experts. The variant is blamed directly for rapidly rising case numbers and deaths throughout the United States. Genetic variants of SARS-CoV-2 have been emerging and circulating around the world during the COVID-19 pandemic, but the Delta variant seems to be especially dangerous, according to the [Centers for Disease Control and Prevention]( (CDC). As a result, the CDC and the U.S. State Department each raised their warnings to the highest levels on July 19 for travel to the United Kingdom. The CDC cautioned to “avoid” traveling there, while the State Department declared a “do not travel” warning for the United Kingdom. A variant has one or more mutations that differentiate it from other COVID-19 varieties in circulation. The Delta variant is turning into the dominant coronavirus strain in the United States, according to the CDC. With more than half the U.S. population not fully vaccinated, public health officials caution that a further resurgence of COVID-19 cases may occur this fall when many unvaccinated children return to school. As of Aug. 3, 192,120,576 people, or 57.9% of the U.S. population, have received at least one dose of a COVID-19 vaccine. Those who are fully vaccinated total 165,081,416, or 49.7%, of the U.S. population, [according to the CDC](. The Food and Drug Administration recently approved a third COVID-19 vaccine, manufactured by [Johnson & Johnson]( ([NYSE:JNJ]( which requires just one dose rather than two, as is required with the first two vaccine providers: [Pfizer]( (NYSE:PFE) and Moderna (NASDAQ:MRNA). COVID-19 cases worldwide have reached 199,455,828 and caused 4,244,422 deaths, as of Aug. 3, according to [Johns Hopkins University](. U.S. COVID-19 cases reached 35,224,145 and caused 614,244 deaths. America has the dreaded distinction as the country with the most COVID-19 cases and deaths. The five innovation stocks to buy are recommended as ways to profit amid the pandemic. Rising COVID-19 cases and deaths add risk to any stock purchases but improving economic data and a recent $1.9 trillion federal stimulus package should help to lift the prices of innovation stocks that show strong promise. Paul Dykewicz, [www.pauldykewicz.com](, is an accomplished, award-winning journalist who has written for Dow Jones, the [Wall Street Journal](, Investor’s Business Daily, USA Today, the Journal of Commerce, Seeking Alpha, GuruFocus and other publications and websites. Paul, who can be followed on Twitter [@PaulDykewicz](, is the editor of  [StockInvestor.com]( and  [DividendInvestor.com]( a writer for both websites and a columnist. He further is editorial director of Eagle Financial Publications in Washington, D.C., where he edits monthly investment newsletters, time-sensitive trading alerts, free e-letters and other investment reports. Paul previously served as business editor of Baltimore’s Daily Record newspaper. Paul also is the author of an inspirational book, [“Holy Smokes! Golden Guidance from Notre Dame’s Championship Chaplain](,” with a foreword by former national championship-winning football coach Lou Holtz. The book is great as a gift and is endorsed by Joe Montana, Joe Theismann, Ara Parseghian, “Rocket” Ismail, Reggie Brooks, Dick Vitale and many others. Call 202-677-4457 for special pricing! Progress in increasing the number of people vaccinated from [COVID-19]( lifts hope that new cases and deaths will keep falling. As of July 19, 186,317,651 people, or 56.1% of the U.S. population, have received at least one dose of a COVID-19 vaccine. The fully vaccinated total 161,473,715 people, or 48.6%, of the U.S. population, [according to the CDC](. The Food and Drug Administration recently approved a third COVID-19 vaccine, manufactured by [Johnson & Johnson]( ([NYSE:JNJ]( which requires only one dose rather than two, as with the first two vaccine providers: [Pfizer]( (NYSE:PFE) and Moderna (NASDAQ:MRNA). COVID-19 cases worldwide have reached 191,216,295 and caused 4,101,590 deaths, as of July 20, according to [Johns Hopkins University](. U.S. COVID-19 cases reached 34,150,195 and caused 609,377 deaths. America has the dreaded distinction as the country with the most COVID-19 cases and deaths. The five innovative investments allow investors to profit amid the pandemic. Rising COVID-19 vaccine availability, improving economic data and a recent $1.9 trillion federal stimulus package should help to lift the prices of the investments to buy. Sincerely, Paul Dykewicz, Editor [StockInvestor.com]( About Paul Dykewicz: Paul Dykewicz is an accomplished, award-winning journalist who has written for Dow Jones, the Wall Street Journal, Investor’s Business Daily, USA Today, Seeking Alpha, GuruFocus and other publications and websites. Paul is the editor of [StockInvestor.com]( and [DividendInvestor.com]( a writer for both websites and a columnist. He further is the editorial director of Eagle Financial Publications in Washington, D.C., where he edits monthly investment newsletters, time-sensitive trading alerts, free e-letters and other investment reports. Paul also is the author of an inspirational book, "[Holy Smokes! Golden Guidance from Notre Dame's Championship Chaplain](", with a foreword by former national championship-winning football coach Lou Holtz. Follow Paul on Twitter [@PaulDykewicz](. mailto:CustomerService@EagleFinancialPublications.com About Us: Eagle Financial Publications is located in Washington, D.C. – only a few blocks from the Capitol. Our products have been helping investors build their wealth for several decades. Whether you’re a long-term investor or short-term trader, you’ll find the right strategy for you, including how to earn more steady income to spend now, preserve and grow your capital to enjoy later, and whatever other investment goals you have. Visit Our Websites: - [StockInvestor.com]( - [DividendInvestor.com]( - [BryanPerryInvesting.com]( - [JimWoodsInvesting.com]( - [MarkSkousen.com]( - [RetirementWatch.com]( - [InvestmentHouse.com]( To ensure future delivery of Eagle Financial Publication's emails please add the domain @info2.eaglefinancialpublications.com to your address book or contact list. This email was sent to [{EMAIL}](MAILTO:{EMAIL}) because you are subscribed to the Eagle Stock Investor Insights List. To unsubscribe please click [here](. View this email in your [web browser](. If you have questions, please send them to [Customer Service](mailto:customerservice@eaglefinancialpublications.com?SUBJECT=Question about _ELETTERS Stock Investor Insights). Eagle Financial Publications - Eagle Products, LLC. - a Caron Broadcasting Company 122 C Street NW, Suite 515 | Washington, D.C. 20001 © Eagle Financial Publications. All rights reserved. [Link](